Overview
Jianhao Lin practices practicing medicine in Guangzhou, China.
Their clinical expertise encompasses Hemangiopericytoma, Epidural Hematoma, Solitary Fibrous Tumor, and Spinal Tumor.
They are actively involved in clinical research, co-authoring 19 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Jianhao Lin
Is Jianhao Lin a top-rated expert for Hemangiopericytoma?
MediFind is an objective health platform that identifies experts based on real-world data. Jianhao Lin is classified as an Experienced expert for Hemangiopericytoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Jianhao Lin participate in research or clinical trials?
Yes. Jianhao Lin has published 19 articles and abstracts on conditions like Hemangiopericytoma. You can view a list of Jianhao Lin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Epidural HematomaLin isExperienced. Learn about Epidural Hematoma.
- HemangiopericytomaLin isExperienced. Learn about Hemangiopericytoma.
- Solitary Fibrous TumorLin isExperienced. Learn about Solitary Fibrous Tumor.
- Spinal TumorLin isExperienced. Learn about Spinal Tumor.